Coronavirus channel feed

US ships out all re­main­ing sup­plies of the on­ly Covid mAb treat­ment that works against Omi­cron

4 years ago

Pfiz­er plans to study a third shot for its Covid-19 vac­cine in the youngest kids, push­ing back its time­line far­ther

4 years ago

Covid-19 roundup: CDC rec­om­mends mR­NA vac­cines over J&J’s due to rare blood clots; EU con­sid­ers deal for vari­ant-spe­cif­ic dos­es of Pfiz­er/BioN­Tech vac­cine

4 years ago

Covid-19 roundup: EMA of­fers ear­ly ac­cess to Pfiz­er's pill Paxlovid; Val­ne­va fires back with boost­er da­ta of its own

4 years ago

US paus­es dis­tri­b­u­tion of GSK/Vir's Covid mAb not due to Omi­cron, but greater sup­ply of Eli Lil­ly mAbs

4 years ago

A new an­ti­body treat­ment of­fers long-await­ed hope for im­muno­com­pro­mised pa­tients, if Omi­cron does­n't get here first

4 years ago
In Focus

Sanofi and Glax­o­SmithK­line: Those PhI­II Covid-19 vac­cine re­sults you’ve been wait­ing for? Wait longer (but here's some boost­er da­ta)

4 years ago
Pharma

Mesoblast shares tank af­ter No­var­tis aban­dons a part­ner­ship for the biotech's po­ten­tial Covid-19 treat­ment

4 years ago
Deals

Ef­fi­ca­cy of Pfiz­er's Covid pill holds up in fi­nal analy­sis, re­duc­ing risk of hos­pi­tal­iza­tion or death by al­most 90%

4 years ago

Ada­gio raised $750M+ for an an­ti­body against fu­ture vari­ants. It failed against Omi­cron

4 years ago

Covid-19 roundup: Study sug­gests Omi­cron vari­ant could es­cape pro­tec­tion of Pfiz­er/BioN­Tech vac­cine; Serum In­sti­tute pre­pares launch of No­vavax shot for chil­dren — re­port

4 years ago

Genen­tech's tocilizum­ab short­age due to Covid-19 now hits CAR-T re­cip­i­ents, with FDA of­fer­ing al­ter­na­tives to help

4 years ago
FDA+

Covid-19 roundup: French reg­u­la­tors not ready to give mol­nupi­ravir the OK; Brii claims Chi­na’s first an­ti­body is ef­fec­tive against Omi­cron

4 years ago

Covid-19 roundup: UK preps for a wave of Omi­cron cas­es; Bourla sug­gests a fourth dose might be nec­es­sary

4 years ago

Covid-19 man­u­fac­tur­ing roundup: Co­v­ax, In­di­an man­u­fac­tur­er at odds over vac­cine sup­ply; EU plan­ning sur­plus on shot pro­duc­tion

4 years ago
Manufacturing

Will ‘orig­i­nal anti­genic sin’ un­der­mine Omi­cron boost­ers? New re­search sug­gests ‘no’

4 years ago
Discovery

Of­fer­ing a long-await­ed op­tion for the un­vac­ci­nat­ed, FDA au­tho­rizes As­traZeneca's long-act­ing pre­ven­ta­tive an­ti­body

4 years ago
FDA+

Omi­cron is a test for the next pan­dem­ic. Will the world keep mak­ing the same mis­takes?

4 years ago
In Focus

New stud­ies in­di­cate mR­NA vac­cines pro­vide lim­it­ed pro­tec­tion against Omi­cron, but boost­ers and new shots may be cru­cial

4 years ago
R&D

Covid-19 roundup: Plant-based shot proves safe, 71% ef­fi­ca­cious in PhI­II; Bourla ex­pects an­tivi­ral to launch this month

4 years ago

WHO rec­om­mends against the use of con­va­les­cent plas­ma for Covid-19

4 years ago

Covid-19 roundup: Val­ne­va de­fends vac­cine in wake of un­flat­ter­ing boost­er study; Mer­ck goes af­ter Pfiz­er’s new an­tivi­ral — re­port

4 years ago

Gilead re­calls 2 lots of Vek­lury af­ter in­ves­ti­ga­tion con­firms com­plaint of glass par­tic­u­lates

4 years ago

Re­searchers move clos­er to de­ci­pher­ing blood clots from As­traZeneca, J&J's Covid-19 vac­cines

4 years ago
Discovery
First page Previous page 15161718192021 Next page Last page
A service from the Financial Times